Merkel Cell Carcinoma: Is there a Role for 2-Deoxy-2-[F-18]fluoro-d-glucose-Positron Emission Tomography/Computed Tomography?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
2-Deoxy-2-[F-18]fluoro-d-glucose (FDG)–positron emission tomography (PET)/computed tomography (CT) is becoming widely available as a powerful imaging modality, combining the ability to detect active metabolic processes and their morphologic features in a single study. The role of FDG-PET/CT is proven in lymphoma, melanoma, colorectal carcinoma, and other cancers. However, there are rare malignancies such as Merkel cell carcinoma that can potentially be evaluated with PET/CT. We were therefore prompted to review our experience with FDG-PET/CT in the management of patients with Merkel cell carcinoma.
This is a retrospective case series of six patients with Merkel cell carcinoma, 58–81 years old (average 69 ± 8.3), who had whole-body PET/CT at our institution from January 1st, 2003 to August 31st, 2005. Two patients were women and four were men. Reinterpretation of the imaging studies for accuracy and data analysis from medical records were performed.
Twelve examinations were acquired for the six patients (one patient had six PET/CT, one patient had two PET/CT, and four patients had one PET/CT). The injected FDG doses ranged 381.1–669.7 MBq (average 573.5 ± 70.3). Four patients had the PET/CT as part of initial staging, and two patients had the exam for restaging (after surgery and XRT). A total of six Merkel lesions (pancreas, adrenal, lip, submandibular lymph nodes, cervical lymph nodes, and parapharyngeal soft tissue) were identified in three patients and confirmed on histopathological examination. The FDG uptake in these areas was intense, with maximum standardized uptake value (SUVmax) values of 5–14 (average 10.4 ± 3.8). In one patient, the PET/CT scan identified abnormal focal distal sigmoid uptake that was biopsied and diagnosed as adenocarcinoma. Two patients had negative scans and had no clinical evidence of disease on follow-up office visits (up to one year after PET/CT).
This case series suggests that FDG-PET/CT may have a promising role in the management of patients with Merkel cell carcinoma.
- Nghiem P, McKee PH, Haynes HA (2001) Merkel cell (cutaneous neuroendocrine) carcinoma. In: Sober AJ, Haluska FG (eds) Skin cancer. Hamilton, Ontario: BC Decker Inc., pp 127–141
- Toker C (1972, January) Trabecular carcinoma of the skin. Arch Dermatol 105(1):107–110, January CrossRef
- Sidhu GS, Chandra P, Cassai ND (2005, May–August) Merkel cells, normal and neoplastic: an update. Ultrastruct Pathol 29(3–4):287–294 CrossRef
- Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG (2005, April 1) Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 23(10):2300–2309 CrossRef
- Gambhir SS (2002, September) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2(9):683–693 CrossRef
- Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL (1999, November) Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 213(2):521–525
- Wasserberg N, Schachter J, Fenig E, Feinmesser M, Gutman H (2000, February) Applicability of the sentinel node technique to Merkel cell carcinoma. Dermatol Surg 26(2):138–141 CrossRef
- Durani BK, Klein A, Henze M, Haberkorn U, Hartschuh W (2003, June) Somatostatin analogue scintigraphy in Merkel cell tumours. Br J Dermatol 148(6):1135–1140 CrossRef
- Castagnoli A, Biti G, De Cristofaro MT, et al. (1992) Merkel cell carcinoma and iodine-131 metaiodobenzylguanidine scan. Eur J Nucl Med 19(10):913–916 CrossRef
- Watanabe N, Shimizu M, Kageyama M, Kitagawa K, Hayasaka S, Seto H (1998, August) 123I-MIBG SPECT of Merkel cell carcinoma. Br J Radiol 71(848):886–887
- Von Moll L, McEwan AJ, Shapiro B, et al. (1987, June) Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. J Nucl Med 28(6):979–988
- Lampreave JL, Benard F, Alavi A, Jimenez-Hoyuela J, Fraker D (1998, December) PET evaluation of therapeutic limb perfusion in Merkel's cell carcinoma. J Nucl Med 39(12):2087–2090
- Wong CO, Pham AN, Dworkin HJ (2000, March) F-18 FDG Accumulation in an Octreotide negative Merkel cell tumor. Clin Positron Imaging 3(2):71–73 CrossRef
- Nguyen BD (2002, December) Positron emission tomographic imaging of Merkel cell carcinoma. Clin Nucl Med 27(12):922–923 CrossRef
- Lin O, Thomas A, Singh A, Greenspan B (2004, November) Complementary role of positron emission tomography in Merkel cell carcinoma. South Med J 97(11):1110–1112 CrossRef
- Yao M, Smith RB, Hoffman HT, Funk GF, Graham MM, Buatti JM (2005, April) Merkel cell carcinoma: two case reports focusing on the role of fluorodeoxyglucose positron emission tomography imaging in staging and surveillance. Am J Clin Oncol 28(2):205–210 CrossRef
- Scanga DR, Martin WH, Delbeke D (2004, February) Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin Nucl Med 29(2):86–90 CrossRef
- Talbot JN, Kerrou K, Missoum F, et al. (2005, August 5) 6-[F-18]Fluoro-L: -DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]Fluoro-d: -glucose positron emission tomography or pentetreotide-(111In) SPECT Data. Mol Imaging Biol 1–5
- Merkel Cell Carcinoma: Is there a Role for 2-Deoxy-2-[F-18]fluoro-d-glucose-Positron Emission Tomography/Computed Tomography?
Molecular Imaging and Biology
Volume 8, Issue 4 , pp 212-217
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Merkel cell
- Industry Sectors
- Author Affiliations
- 1. Division of Nuclear Medicine, Department of Radiology, Stanford University Medical Center, 300 Pasteur Drive, H-0101, Stanford, CA, 94305, USA
- 2. Division of Nuclear Medicine, Departments of Radiology and Bioengineering, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, James H. Clark Center, 318 Campus Drive, 150 East Wing, 1st Floor, Stanford, CA, 94305-5427, USA